Shares of Corteva dropped 83.6% to $12.76 on October 1 as the company completed a long-anticipated separation of its seed business into a new publicly traded entity called Vylor Inc., distributing one Vylor share for every Corteva share held. The plunge is mechanical — not a panic selloff — but the real question is whether the two standalone companies can justify a combined valuation that exceeds the old Corteva's $77.65 pre-split price. Corteva Cleaves Its Seed Empire Into Vylor — Will Two Focused Ag Players Be Worth More Than One?

Shares of Corteva plunged 83.6% to $12.76 on October 1 as the company completed the spin-off of its seed and genetics business into a new publicly traded company, Vylor Inc. (NYSE: VYLR). Vylor began trading on the New York Stock Exchange under the symbol VYLR, marking its debut as an independent public company. The headline drop is not a collapse — it is the arithmetic of carving the bigger, more profitable half of the business out of the stock ticker. The real question: will investors reward the split with a combined valuation greater than the old Corteva's ~$54 billion market cap?

  • The Seed Business Was the Crown Jewel — and It Left the Building. In Q2 2026, Corteva's Seed segment generated $4.53 billion in revenue and $1.97 billion in operating EBITDA, dwarfing Crop Protection's $1.85 billion in sales and $342 million in EBITDA. Vylor inherited essentially all of that earnings power. The new company is targeting net sales of $11.2–$11.9 billion by 2029, with operating EBITDA of $3.3–$3.7 billion — a growth story built on premium genetics and biotech licensing. Pre-split analyst estimates valued Vylor alone at roughly $58–$67 per share , implying the remaining Corteva stub should trade in the low-to-mid teens — right where it opened.

  • What's Left at Corteva Is a Tougher Sell. The crop-protection business Corteva retains makes herbicides, insecticides, and fungicides — a segment facing 4% revenue declines in Q2, with pricing down 4% on competitive pressure, especially in Brazil.

Management expects new crop-protection products to approach $2 billion in 2026 revenue , but investors will now judge that pipeline on its own, without the seed business padding the income statement.

  • The Tax-Free Structure Keeps Shareholders Whole — On Paper. The spin-off is intended to be tax-free for U.S. federal income tax purposes , meaning holders got one VYLR share for each CTVA share without triggering capital gains. Combined, the two tickers should approximate the old $77.65 close. The interesting setup comes if investors give Vylor a premium valuation, potentially leaving the remaining Corteva trading at a discount that could attract value buyers.

  • Separation Costs and Dis-Synergies Are Real. One-time separation costs are expected to total roughly $350 million, with net dis-synergies — the extra expenses each company bears from running duplicate functions — estimated at ~$100 million annually. Those duplicate costs will need to be offset by sharper strategic focus if the split is to create genuine new value rather than simply rearrange existing earnings.